Key Findings from the NIAGARA Trial at ESMO 2024

The results of the NIAGARA trial were recently presented at ESMO 2024.

The NIAGARA trial, presented at ESMO 2024, compared hypofractionated (3 weeks) and normofractionated (5 weeks) radiation therapy for bladder cancer patients needing nodal irradiation. With 1,265 participants and a 4.8-year follow-up, the trial found that hypofractionated therapy was noninferior in efficacy and had similar rates of lymphedema as normofractionated therapy. This supports hypofractionated therapy as an effective, shorter treatment option.

The principal investigator (PI) for the NIAGARA trial is Thomas Powles.

The results of the NIAGARA trial were recently presented at ESMO24.

Societies and individuals shared their perspectives on social media:

ESMO:

“First practice-changing results presented with immunotherapy plus neoadjuvant chemotherapy in localised muscle-invasive Bladder Cancer. Addition of durvalumab extends survival in the NIAGARA trial.”

Enrique Grande:

“NIAGARA is the first randomized trial to demonstrate significant OS difference in the NIBC perioperative trest.

Tom Powles did it again!!! Another practice changing trial in the back.”

Amol Akhade:

“Esmo Day 3

I guess it’s day of positive trials. Niagara.

Addition of Durvalumab to NACT followed by Adjuvant Durvalumab improves both EFS and OS.

EFS HR – 0.68
OS HR – 0.75

Durvalumab did not affect rate of radical cycstetomy.

Looking forward to full preparation.”

Andreas Koulouris:

“Practice-changing data from the Phase 3 NIAGARA trial with perioperative Durvalumab show an OS benefit in muscle-invasive Bladder Cancer. Excellent presentation by Petros Grivas at ESMO24.”

Balazs Halmos:

“Wow-just a NIAGARA waterfall of practice changing studies in NEJM from ESMO2024 – i count 8- a record??? NEJM= New ESMO Journal of Mindblowing progress? Just thinking of what metastatic melanoma meant when i was a fellow- practically guaranteed death- now 50% 10 yrs+ survival!”

Amanada Psyrri:

“Wonderful discussion of practice-changing Niagara study (Powles T et al) by Petros Grivas at the Presidential session of ESMO 2024.”

More posts featuring ESMO24 on oncodaily.com